• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care

    7/13/26 8:30:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care
    Get the next $ENOV alert in real time by email
    • CT-RevitL™ launches in the United States, built on a foundation of 150+ published studies on photobiomodulation (PBM) therapy
    • Designed to deliver deeper, faster and more consistent therapeutic outcomes for animals

    DALLAS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology company, today announced the U.S. launch of CT-RevitL™, the next-generation veterinary PBM laser therapy system from its Companion Animal Health business. CT-RevitL delivers enhanced clinical performance, greater mobility and a more intuitive treatment experience for veterinary teams and their patients.

    Laser therapy is one of the fastest-growing modalities in veterinary medicine, used to manage pain, accelerate tissue healing, reduce inflammation and support post-operative recovery across a wide range of musculoskeletal and soft-tissue conditions.¹ As pet owners increasingly seek drug-sparing alternatives and practices look for tools that improve both clinical outcomes and practice efficiency, demand for advanced laser therapy continues to grow.²

    Companion Animal Health, an Enovis business and the U.S. market leader in veterinary therapeutic laser technology, has spent more than 15 years advancing the science and clinical application of PBM laser therapy. CT-RevitL uses Companion’s new COMPASS technology, an intelligent treatment guidance system that delivers precise, calibrated dosing to help reduce treatment variability and support consistent application across users. By making high-powered laser therapy simpler to deliver and easier to integrate into everyday practice workflows, COMPASS helps veterinary teams provide treatment with greater confidence and efficiency.³

    "CT-RevitL represents the next chapter in our commitment to deliver practical, innovative, evidence-based veterinary care," said Terry Ross, Group President of Enovis’ Prevention & Recovery business segment, which includes Companion Animal Health. "We have been the trusted partner of veterinary teams across the U.S. for nearly two decades, and CT-RevitL extends that leadership by giving practitioners a more intuitive and consistent way to deliver laser therapy. It is a meaningful step forward for the pets we care for, the practices that rely on us, and the broader advancement of laser therapy as a standard of care in veterinary medicine."

    Beyond its clinical applications, CT-RevitL is designed to support practice growth by expanding treatment offerings, encouraging repeatable protocols and helping practices generate recurring demand for non-drug care. By supporting routine use across a broad range of conditions, the system can help practices improve return on investment, strengthen client satisfaction and differentiate themselves as providers of advanced veterinary care.

    CT-RevitL is available to veterinary practices across the United States beginning July 13, 2026, with international availability anticipated in subsequent phases. The launch is supported by a comprehensive clinical education program and ongoing partnership from Companion’s veterinary specialists. For more information, visit www.companionanimalhealth.com.

    About Enovis

    Enovis™ (NYSE:ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. Enovis solutions impact the well-being of millions of patients wherever they are on their pathway to health. Discover more about Enovis at www.enovis.com.

    About Companion Animal Health

    Companion Animal Health, a division of Enovis, is a global leader in veterinary medical technology and education. We believe in enhancing animal well-being by providing advanced, non-invasive treatments—such as laser therapy and targeted regenerative solutions—that promote faster healing and pain management. Headquartered in Newark, Delaware, we support veterinary professionals worldwide with innovative equipment and clinical support. For more information, visit www.companionanimalhealth.com.

    Trademark Notice

    Enovis, CT-RevitL, and Companion Animal Health are trademarks or registered trademarks of Enovis™ Corporation or its affiliates.

    Media Contact

    Cristina Pasquino

    Enovis Corporation

    Cristina.Pasquino@enovis.com

    References

    ¹ Riegel RJ, Godbold JC. Laser Therapy in Veterinary Medicine: Photobiomodulation. Wiley-Blackwell; 2017.

    ² Pryor B, Millis DL. Therapeutic laser in veterinary medicine. Vet Clin North Am Small Anim Pract. 2015;45(1):45-56. doi:10.1016/j.cvsm.2014.09.003.

    ³ Companion Animal Health. Publications: scientific studies on photobiomodulation and laser therapy. Available at: publications.companionanimalhealth.com.

    Attachment

    • Companion Animal Health CT-RevitL™


    Cristina Pasquino
    Enovis Corporation
    Cristina.Pasquino@enovis.com

    Primary Logo

    Get the next $ENOV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENOV

    DatePrice TargetRatingAnalyst
    7/9/2026$29.00Outperform
    BMO Capital Markets
    4/17/2026Outperform
    William Blair
    1/6/2026$41.00Buy
    BTIG Research
    10/3/2024$62.00Mkt Outperform
    JMP Securities
    6/13/2024$53.00Neutral
    JP Morgan
    2/13/2024$72.00Overweight
    Stephens
    1/22/2024$75.00Buy
    UBS
    1/3/2024Outperform
    William Blair
    More analyst ratings

    $ENOV
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Enovis Corporation

    SCHEDULE 13G/A - Enovis CORP (0001420800) (Subject)

    7/8/26 10:52:13 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form 11-K filed by Enovis Corporation

    11-K - Enovis CORP (0001420800) (Filer)

    6/26/26 4:55:48 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SD filed by Enovis Corporation

    SD - Enovis CORP (0001420800) (Filer)

    5/28/26 5:21:46 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BMO Capital Markets initiated coverage on Enovis Corporation with a new price target

    BMO Capital Markets initiated coverage of Enovis Corporation with a rating of Outperform and set a new price target of $29.00

    7/9/26 9:28:05 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    William Blair resumed coverage on Enovis Corporation

    William Blair resumed coverage of Enovis Corporation with a rating of Outperform

    4/17/26 8:10:50 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    BTIG Research initiated coverage on Enovis Corporation with a new price target

    BTIG Research initiated coverage of Enovis Corporation with a rating of Buy and set a new price target of $41.00

    1/6/26 8:55:57 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ortiz Christine was granted 846 shares, increasing direct ownership by 3% to 25,857 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    7/1/26 9:00:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Chief Administrative Officer Engert Oliver bought $20,920 worth of shares (1,000 units at $20.92), increasing direct ownership by 2% to 53,640 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    6/16/26 9:05:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Amendment: Chief Administrative Officer Engert Oliver was granted 1,000 shares, increasing direct ownership by 2% to 52,640 units (SEC Form 4)

    4/A - Enovis CORP (0001420800) (Issuer)

    6/16/26 9:00:04 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Administrative Officer Engert Oliver bought $20,920 worth of shares (1,000 units at $20.92), increasing direct ownership by 2% to 53,640 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    6/16/26 9:05:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Chief Administrative Officer Engert Oliver bought $25,948 worth of shares (1,200 units at $21.62), increasing direct ownership by 2% to 51,840 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    6/15/26 9:00:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Chief Administrative Officer Engert Oliver bought $23,000 worth of shares (1,000 units at $23.00), increasing direct ownership by 2% to 50,640 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    6/11/26 9:00:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Financials

    Live finance-specific insights

    View All

    Enovis to Host Second Quarter 2026 Results Conference Call on August 6th

    Dallas, TX, July 17, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2026 financial results on Thursday, August 6th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (800) 715-9

    7/17/26 8:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Announces First Quarter 2026 Results

    First-quarter sales growth of 5% on a reported basisFirst-quarter Reconstructive sales grew 11% on a reported basisReiterating full-year 2026 revenue, adjusted EBITDA, adjusted EPS, and Free Cash Flow Conversion guidance Dallas, TX, May 07, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 3, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2026 Financial Results Enovis' first-quarter net sales of $589 million grew 5% on a reported basis and 3

    5/7/26 6:01:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis to Host First Quarter 2026 Results Conference Call on May 7th

    Dallas, TX, April 10, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2026 financial results on Thursday, May 7th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (800) 715-987

    4/10/26 8:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Leadership Updates

    Live Leadership Updates

    View All

    Enovis Appoints Oliver Engert as Chief Administrative Officer

    Dallas, TX, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology company, has announced that Oliver Engert has been appointed Chief Administrative Officer, effective today. In this newly-created role, Oliver will be responsible for leading Enovis' strategy development, driving organizational efficiency and enhancing operational excellence to support the company in its next phase of profitable, capital-efficient growth. Damien McDonald, CEO of Enovis said, "Oliver's appointment comes at a very exciting time for Enovis. As we take steps to build on our strong foundation and unlock our future potential, his extensive knowledge, skills a

    1/5/26 4:15:00 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

    Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "The Company") (NYSE:ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at th

    4/2/25 6:30:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600

    NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE:ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE:ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE:CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. Following completion of the merger, CONSOL Energy will be renamed Core Natural Resources Inc., and its ticker will change to CNR. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index

    1/7/25 6:19:00 PM ET
    $ARCH
    $CART
    $CEIX
    Coal Mining
    Energy
    Real Estate
    Industrial Specialties

    $ENOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enovis to Host Second Quarter 2026 Results Conference Call on August 6th

    Dallas, TX, July 17, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2026 financial results on Thursday, August 6th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (800) 715-9

    7/17/26 8:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care

    CT-RevitL™ launches in the United States, built on a foundation of 150+ published studies on photobiomodulation (PBM) therapy Designed to deliver deeper, faster and more consistent therapeutic outcomes for animals DALLAS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology company, today announced the U.S. launch of CT-RevitL™, the next-generation veterinary PBM laser therapy system from its Companion Animal Health business. CT-RevitL delivers enhanced clinical performance, greater mobility and a more intuitive treatment experience for veterinary teams and their patients. Laser therapy is one of the fastest-growing modalities i

    7/13/26 8:30:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Launches Spinamic® Hybrid Scoliosis Brace, Combining Corrective Performance with Improved Wearability for Children and Teens

    Spinamic combines the curve-correction efficacy of rigid bracing with the comfort and mobility of dynamic braces, offering an optimal balance of therapy and patient wearabilityAvailable in 10 off-the-shelf sizes with an adjustable three-point pressure system, the brace enables fitting, imaging, and adjustment in a single visitSpinamic is now available in the United States, with regulatory clearance being pursued across additional markets worldwide DALLAS, TX, June 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology company, today announced the launch of the DonJoy Spinamic® Hybrid Scoliosis Brace, to be distributed by its subsidiary, DJO,

    6/8/26 8:30:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Enovis Corporation

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    11/14/24 1:28:31 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    4/5/24 12:21:51 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    2/14/24 10:04:36 AM ET
    $ENOV
    Industrial Specialties
    Health Care